The superiority of 3-dimensional BC models in the context of drug development was also demonstrated by Wei et al., who compared the sensitivities of BC cell lines and of patient-derived organoids (PDOs) to cisplatin, the Bcl-2 inhibitor venetoclax and the MCL1 inhibitor S63845 [13▪]. This evidence concerns the gene BCL2 and breast cancer.